Literature DB >> 24633026

Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin.

Takahisa Furuta1, Mitsushige Sugimoto, Mihoko Yamade, Takahiro Uotani, Shu Sahara, Hitomi Ichikawa, Takuma Kagami, Takanori Yamada, Satoshi Osawa, Ken Sugimoto, Hiroshi Watanabe, Kazuo Umemura.   

Abstract

Eradication of H. pylori in patients allergic to penicillin should be performed using regimens without penicillin derivatives. We treated a total of 28 patients allergic to penicillin with a proton pump inhibitor (PPI), metronidazole (250 mg bid) and sitafloxacin (100 mg bid) for one to two weeks. At four to eight weeks after the treatment, the patients underwent the [(13)C]-urea breath test. The overall eradication rate was 100.0%. Mild adverse events were observed. Triple therapy with a PPI, metronidazole and sitafloxacin is well tolerated and effective for the eradication of H. pylori in patients allergic to penicillin.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24633026     DOI: 10.2169/internalmedicine.53.1677

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  9 in total

1.  ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.

Authors:  William D Chey; Grigorios I Leontiadis; Colin W Howden; Steven F Moss
Journal:  Am J Gastroenterol       Date:  2017-01-10       Impact factor: 10.864

2.  Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.

Authors:  Javier P Gisbert; Jesús Barrio; Inés Modolell; Javier Molina-Infante; Angeles Perez Aisa; Manuel Castro-Fernández; Luis Rodrigo; Angel Cosme; Jose Luis Gisbert; Miguel Fernández-Bermejo; Santiago Marcos; Alicia C Marín; Adrián G McNicholl
Journal:  Dig Dis Sci       Date:  2014-09-19       Impact factor: 3.199

3.  Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients.

Authors:  Hideki Mori; Hidekazu Suzuki; Juntaro Matsuzaki; Tatsuhiro Masaoka; Takanori Kanai
Journal:  United European Gastroenterol J       Date:  2017-01-19       Impact factor: 4.623

4.  First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin.

Authors:  Soichiro Sue; Nobumi Suzuki; Wataru Shibata; Tomohiko Sasaki; Hiroaki Yamada; Hiroaki Kaneko; Toshihide Tamura; Tomohiro Ishii; Masaaki Kondo; Shin Maeda
Journal:  Gastroenterol Res Pract       Date:  2017-10-18       Impact factor: 2.260

Review 5.  Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan.

Authors:  Mitsushige Sugimoto; Yoshio Yamaoka
Journal:  Front Pharmacol       Date:  2019-01-15       Impact factor: 5.810

6.  Helicobacter pylori rescue treatment with vonoprazan, metronidazole, and sitafloxacin in the presence of penicillin allergy.

Authors:  Soichiro Sue; Tomohiko Sasaki; Hiroaki Kaneko; Kuniyasu Irie; Masaaki Kondo; Shin Maeda
Journal:  JGH Open       Date:  2021-01-23

Review 7.  Treatment of Helicobacter pylori infection in the presence of penicillin allergy.

Authors:  Amit Kumar Dutta; Perminder Singh Phull
Journal:  World J Gastroenterol       Date:  2021-11-28       Impact factor: 5.742

8.  Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology.

Authors:  Shivaram Prasad Singh; Vineet Ahuja; Uday C Ghoshal; Govind Makharia; Usha Dutta; Showkat Ali Zargar; Jayanthi Venkataraman; Amit Kumar Dutta; Asish K Mukhopadhyay; Ayaskanta Singh; Babu Ram Thapa; Kim Vaiphei; Malathi Sathiyasekaran; Manoj K Sahu; Niranjan Rout; Philip Abraham; Prakash Chandra Dalai; Pravin Rathi; Saroj K Sinha; Shobna Bhatia; Susama Patra; Ujjala Ghoshal; Ujjal Poddar; Venigalla Pratap Mouli; Vikram Kate
Journal:  Indian J Gastroenterol       Date:  2021-07-05

9.  A significant increase in the pepsinogen I/II ratio is a reliable biomarker for successful Helicobacter pylori eradication.

Authors:  Hiroki Osumi; Junko Fujisaki; Takanori Suganuma; Yusuke Horiuchi; Masami Omae; Toshiyuki Yoshio; Akiyoshi Ishiyama; Tomohiro Tsuchida; Kazumasa Miki
Journal:  PLoS One       Date:  2017-08-30       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.